Development of Novel Lysosome-Targeting Chimera by Non-covalent–Type Fc-IGF2 Complex (Fc-LYTAC) for Target Membrane Protein Degradation

Le résumé fourni par la source

The development of selective inducers of extracellular or membrane protein degradation has attracted attention as next-generation drugs. Herein, we report a novel lysosome-targeting chimera (LYTAC) comprising a fusion protein (G67-(GGGGS)n-IGF2), in which insulin-like growth factor 2 (IGF2) is linked to an Fc-binding peptide derived from protein G (G67) via several repeats of a GGGGS linker (n = 0–3). G67-(GGGGS)n-IGF2 forms non-covalent complexes with the Fc region of the Fc domain–containing proteins. The trastuzumab-based human epidermal growth factor receptor 2 (HER2) targeting Fc-LYTAC (FcL-2) markedly induced HER2 degradation. The HER2 degradation activity of FcL-2 was inhibited by the inhibition of lysosomal activities, indicating that Fc-LYTAC induces target protein degradation via the endocytosis-lysosomal pathway. The Fc-LYTAC methodology could be extended to epidermal growth factor receptor–binding antibodies and even Fc-tagged HER2-binding single-chain variable fragments. These results provide an innovative strategy for the conversion of membrane protein–binding molecules with an Fc region into efficient target protein degradation inducers.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.